参考文献/References:
[1] Rubin LA,Urowitz MB,Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited[J]. Q J Med,1985,55(216):87-98.
[2] Kiani AN,Magder LS,Post WS,et al. Coronary calcification in SLE:comparison with the multi-ethnic study of atherosclerosis[J]. Rheumatology(Oxford), 2015,54(11):1976-1981.
[3] Manzi S,Meilahn EN,Rairie JE,et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus:comparison with the Framingham study[J]. Am J Epidemiol,1997,145(5):408-415.
[4] McMahon M,Skaggs BJ,Grossman JM,et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus[J]. Arthritis Rheumatol,2014,66(1):130-139.
[5] Szalai AJ,Alarcón GS,Calvo-Alén J,et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA).XXX:association between c-reactive protein (CRP) gene polymorphisms and vascular events[J]. Rheumatology (Oxford), 2005,44(7):864-868.
[6] Costenbader KH,Kim DJ,Peerzada J,et al. Cigarette smoking and the risk of systemic lupus erythematosus:a meta-analysis[J]. Arthritis Rheum, 2004,50(3):849-857.
[7] Kiani AN,Post WS,Magder LS,et al. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus[J]. Rheumatology (Oxford),2011,50(11):2071-2079.
[8] Arnson Y,Shoenfeld Y,Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity[J]. J Autoimmun,2010,34(3):J258-265.
[9] Parker B,Urowitz MB,Gladman DD,et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus:data from an international inception cohort[J]. Ann Rheum Dis,2015,74(8):1530-1536.
[10] 冉久举,汪汉,蔡琳. 冠状动脉粥样硬化性心脏病饮食因素的研究进展[J].心血管病学进展,2014,35(6):729-733.
[11] Schanberg LE,Sandborg C,Barnhart HX,et al. Premature atherosclerosis in pediatric systemic lupus erythematosus:risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort[J]. Arthritis Rheum,2009,60(5):1496-1507.
[12] Tektonidou MG,Kravvariti E,Konstantonis G,et al. Subclinical atherosclerosis in systemic lupus erythematosus:comparable risk with diabetes mellitus and rheumatoid arthritis[J]. Autoimmun Rev,2017,16(3):308-312.
[13] Sabio JM,Martinez-Bordonado J,Sánchez-Berná I,et al. Nighttime blood pressure patterns and subclinical atherosclerosis in women with systemic lupus erythematosus[J]. J Rheumatol,2015,42(12):2310-2317.
[14] Tselios K,Koumaras C,Gladman DD,et al. Dyslipidemia in systemic lupus erythematosus:just another comorbidity?[J]. Semin Arthritis Rheum, 2016,45(5):604-610.
[15] Volkmann ER,Grossman JM,Sahakian LJ,et al. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken),2010,62(2):258-265.
[16] Olusi SO,George S. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus[J]. Vasc Health Risk Manag,2011,7:75-80.
[17] Gu L,Johnson MW,Lusis AJ. Quantitative trait locus analysis of plasma lipoprotein levels in an autoimmune mouse model:interactions between lipoprotein metabolism,autoimmune disease, and atherogenesis[J]. Arterioscler Thromb Vasc Biol,1999,19(2):442-453.
[18] Sánchez-Pérez H,Tejera-Segura B,de Vera-González A,et al. Insulin resistance in systemic lupus erythematosus patients:contributing factors and relationship with subclinical atherosclerosis[J]. Clin Exp Rheumatol,2017,35(6):885-892.
[19] Refai TM,Al-Salem IH,Nkansa-Dwamena D,et al.Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients[J]. Clin Rheumatol,2002,21(6):457-461.
[20] Rho YH,Solus J,Raggi P,et al. Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis[J]. Arthritis Care Res (Hoboken),2011,63(4):535-541.
[21] Roman MJ,Shanker BA,Davis A,et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus[J]. N Engl J Med,2003,349(25):2399-2406.
[22] Tselios K,Urowitz MB. Cardiovascular and pulmonary manifestations of systemic lupus erythematosus[J]. Curr Rheumatol Rev,2017,13(3):206-218.
[23] Tselios K,Sheane BJ,Gladman DD,et al. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus:a systematic review[J]. J Rheumatol,2016,43(1):54-65.
[24] Sinicato NA,da Silva Cardoso PA,Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus[J]. Curr Cardiol Rev,2013,9(1):15-19.
[25] Duval A,Helley D,Capron L,et al. Endothelial dysfunction in systemic lupus patients with low disease activity:evaluation by quantification and characterization of circulating endothelial microparticles,role of anti-endothelial cell antibodies[J]. Rheumatology (Oxford),2010,49(6):1049-1055.
[26] Harris TB,Ferrucci L,Tracy RP,et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly[J]. Am J Med,1999,106(5):506-512.
[27] Sun L,Liu M,Li R,et al. Hydroxychloroquine,a promising choice for coronary artery disease?[J]. Med Hypotheses,2016,93:5-7.
[28] Manger K,Kusus M,Forster C,et al. Factors associated with coronary artery calcification in young female patients with SLE[J]. Ann Rheum Dis, 2003,62(9):846-850.
[29] Giannelou M,Mavragani CP. Cardiovascular disease in systemic lupus erythematosus:a comprehensive update[J]. J Autoimmun,2017,82:1-12.
[30] Jorge A,Lertratanakul A,Lee J,et al. Depression and progression of subclinical cardiovascular disease in systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken),2017,69(1):5-11.
[31] Hosenpud JD,Montanaro A,Hart MV,et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus[J]. Am J Med,1984,77(2):286-292.
[32] Rivera-López R,Jiménez-Jáimez J,Sabio JM,et al. Relationship between QT interval length and arterial stiffness in systemic lupus erythematosus (SLE):a cross-sectional case-control study[J]. PLoS One,2016,11(4):e0152291.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(3):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(3):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(3):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(3):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(3):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(3):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]